Azenta Announces Strategic Investments to Advance GENEWIZ Capabilities
Azenta, Inc. announced an exclusive licensing agreement with Elegen Corp. and the acquisition of SynPlexity Inc. to expand its GENEWIZ gene synthesis and library offerings.
Stocks · News reference
Needham Reiterates Buy on Azenta, Maintains $37 Price Target
Needham analyst David Saxon reiterates Azenta (NASDAQ:AZTA) with a Buy and maintains $37 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Azenta Announces Acquisition Of Gene Library Maker SynPlexity, Exclusive License With Elegen For DNA Synthesis Technology; Terms Not Disclosed
8-K filing — Azenta, Inc. (AZTA)
Filed: 2026-10-30 AccNo: 0001628280-26-068443 Size: 719 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events
Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Earnings Call
Azenta, Inc. has scheduled its fiscal fourth quarter and full year 2026 financial results conference call for November 11, 2026.
Azenta Joins Rhode Island Life Science Hub Research Initiative
Azenta has been selected as a partner for the Rhode Island Life Science Hub (RILSH) to provide expertise in biospecimen management and secure data systems for a new research program.
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo, PacBio and others posted double-digit gains.